Inventor

Joseph E. Payne

Inventor

San Diego, CA, US

Overview

2009–2021

Patent span

Chemistry

Primary field (CPC C)

Patents· 50 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary

A61KPreparations for medical, dental or toiletry purposes22%

C12NMicroorganisms or enzymes18%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations16%

C07CAcyclic or carbocyclic compounds16%

C07JSteroids6%

C11CFatty acids from fats, oils or waxes5%

C07DHeterocyclic compounds4%

C07HSugars4%

C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium2%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests2%

PatentTitleYear

11,103,583Lipids for therapeutic agent delivery formulations2021 11,084,779Cationic lipids for therapeutic agent delivery formulations2021 10,980,895Ionizable cationic lipid for RNA delivery2021 10,968,248Trinucleotide mRNA cap analogs2021 10,961,181Cationic lipids for therapeutic agent delivery formulations2021 10,961,188Ionizable cationic lipid for RNA delivery2021 10,815,463Messenger UNA molecules and uses thereof2020 10,781,169Method of synthesis of an ionizable cationic lipid2020 10,683,500UNA oligomers having reduced off-target effects in gene silencing2020 10,669,229Compounds for targeting drug delivery and enhancing siRNA activity2020 10,604,758Therapeutic oligomers for treating amyloidosis2020 10,556,861Ionizable cationic lipid for RNA delivery2020 10,532,975Cationic lipids for therapeutic agent delivery formulations2020 10,526,284Ionizable cationic lipid for RNA delivery2020 10,519,447Therapeutic UNA oligomers and uses thereof2019 10,487,105Trinucleotide MRNA cap analogs2019 10,441,659Lipids for therapeutic agent delivery formulations2019 10,421,964UNA oligomers and compositions for treating amyloidosis2019 10,399,937Ionizable cationic lipid for RNA delivery2019 10,383,952Ionizable cationic lipid for RNA delivery2019 10,233,148Aromatic ionizable cationic lipid2019 10,227,302Ionizable cationic lipid for RNA delivery2019 10,196,637Retinoid-lipid drug carrier2019 10,195,145Method for treating fibrosis using siRNA and a retinoid-lipid drug carrier2019 10,100,004Compounds for targeting drug delivery and enhancing siRNA activity2018 10,000,447Compounds for targeting drug delivery and enhancing siRNA activity2018 9,982,259Transthyretin allele selective UNA oligomers for gene silencing2018 9,963,424Cationic lipids for therapeutic agent delivery formulations2018 9,962,449MultiLigand agent for drug delivery2018 9,951,002Ionizable cationic lipid for RNA delivery2018 9,896,413'Ionizable cationic lipid for RNA delivery'2018 9,856,475'Formulations for treating amyloidosis'2018 9,850,202Ionizable cationic lipid for RNA delivery2017 9,834,510Aromatic ionizable cationic lipid2017 9,670,152'Ionizable cationic lipid for RNA delivery'2017 9,593,077'Ionizable cationic lipid for RNA delivery'2017 9,580,711'Lipid particles with asymmetric cationic lipids for RNA delivery'2017 9,567,296'Ionizable cationic lipid for RNA delivery'2017 9,456,984'Method for treating fibrosis using siRNA and a retinoid-lipid drug carrier'2016 9,393,315'Compounds for targeting drug delivery and enhancing siRNA activity'2016 9,365,610'Asymmetric ionizable cationic lipid for RNA delivery'2016 9,308,267'Lipids for therapeutic agent delivery formulations'2016 9,242,001'Cationic lipids for therapeutic agent delivery formulations'2016 9,011,903'Cationic lipids for therapeutic agent delivery formulations'2015 8,741,867'Retinoid-liposomes for treating fibrosis'2014 8,664,376'Retinoid-liposomes for enhancing modulation of HSP47 expression'2014 8,609,852'Thiazolyl mGluR5 antagonists and methods for their use'2013 8,242,143'Thiazolyl mGluR5 antagonists and methods for their use'2012 7,879,882'Thiazolyl mglur5 antagonists and methods for their use'2011 7,495,029'Prodrugs of (2R)-2-propyloctanoic acid for the treatment of stroke'2009

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2009–2021Based in Oceanside, CA, US· patent location history

2013–2016Patents assigned to PAYNE JOSEPH E (5)· patent assignee history

2014–2021Patents assigned to NITTO DENKO CORP (17)· patent assignee history

2014–2016Patents assigned to AHMADIAN MOHAMMAD (4)· patent assignee history

2014–2016Patents assigned to AKOPIAN VIOLETTA (4)· patent assignee history

2016–2021Patents assigned to ARCTURUS THERAPEUTICS INC (27)· patent assignee history

2016–2021Based in San Diego, CA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
ARCTURUS THERAPEUTICS INC	27	2016–2021
NITTO DENKO CORP	17	2014–2021
PAYNE JOSEPH Eself	5	2013–2016
AHMADIAN MOHAMMAD	4	2014–2016
AKOPIAN VIOLETTA	4	2014–2016

Locations

Location	Patents	Span
San Diego, California, US	28	2016–2021
Oceanside, California, US	22	2009–2021